The DOI matches its Crossref record; 261 of the 261 references it cites were found in a registry or an index.
Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy
Abstract
Most solid tumor cells adapt to their heterogeneous microenvironment by depending largely on aerobic glycolysis for energy production, a phenomenon called the Warburg effect, which is a hallmark of cancer. The altered energy metabolism not only provides cancer cell with ATP for cellular energy, but also generate essential metabolic intermediates that play a pivotal role in the biosynthesis of macromolecules, to support cell proliferation, invasiveness, and chemoresistance. The cellular metabolic reprogramming in cancer is regulated by several oncogenic proteins and tumor suppressors such as hypoxia-inducible factor (HIF-1), Myc, p53, and PI3K/Akt/mTOR pathway. A better understanding of the mechanisms involved in the regulation of aerobic glycolysis can help in developing glycolytic inhibitors as anticancer agents. These metabolic antiglycolytic agents could be more effective if used in drug combinations to combat cancer. Several preclinical and early clinical studies have shown the effectiveness of targeting the glycolytic pathway as a therapeutic approach to suppress cancer progression. This review aimed to present the most recent data on the emerging drug candidate targeting enzymes and intermediates involved in glucose metabolism to provide therapeutic opportunities and challenges for antiglycolytic cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
He, T., Zhang, Y.-J., Jiang, H., Li, X.-H., Zhu, H., & Zheng, K.-L. (2015) · Medical Oncology · doi:10.1007/s12032-015-0633-8 · Cited by 130
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683
Targeting mitochondria for cancer therapy
Fulda, S., Galluzzi, L., & Kroemer, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3137 · Cited by 1,629
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
Bonnet, S., Archer, S. L., Allalunis-Turner, J., Haromy, A., Beaulieu, C., Thompson, R., Lee, C. T., Lopaschuk, G. D., Puttagunta, L., Bonnet, S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.10.020 · Cited by 1,530
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
Le, A., Cooper, C. R., Gouw, A. M., Dinavahi, R., Maitra, A., Deck, L. M., Royer, R. E., Vander Jagt, D. L., Semenza, G. L., & Dang, C. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914433107 · Cited by 1,516
Glycolysis inhibition for anticancer treatment
Pelicano, H., Martin, D. S., Xu, R.-H., & Huang, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209597 · Cited by 1,516
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R. N., Pandey, A., & Semenza, G. L. (2011) · Cell · doi:10.1016/j.cell.2011.03.054 · Cited by 1,463
Akt Stimulates Aerobic Glycolysis in Cancer Cells
Elstrom, R. L., Bauer, D. E., Buzzai, M., Karnauskas, R., Harris, M. H., Plas, D. R., Zhuang, H., Cinalli, R. M., Alavi, A., Rudin, C. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2904 · Cited by 1,454
LeBleu, V. S., O’Connell, J. T., Gonzalez Herrera, K. N., Wikman, H., Pantel, K., Haigis, M. C., de Carvalho, F. M., Damascena, A., Domingos Chinen, L. T., Rocha, R. M., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3039 · Cited by 1,404
Tumor glycolysis as a target for cancer therapy: progress and prospects
Ganapathy-Kanniappan, S., & Geschwind, J.-F. H. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-152 · Cited by 1,395
The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma
Pavlides, S., Whitaker-Menezes, D., Castello-Cros, R., Flomenberg, N., Witkiewicz, A. K., Frank, P. G., Casimiro, M. C., Wang, C., Fortina, P., Addya, S., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10238 · Cited by 1,391
Cooperation and Competition in the Evolution of ATP-Producing Pathways
Pfeiffer, T., Schuster, S., & Bonhoeffer, S. (2001) · Science · doi:10.1126/science.1058079 · Cited by 1,354
Anastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J.-K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S., et al. (2011) · Science · doi:10.1126/science.1211485 · Cited by 1,190
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis
Locasale, J. W., Grassian, A. R., Melman, T., Lyssiotis, C. A., Mattaini, K. R., Bass, A. J., Heffron, G., Metallo, C. M., Muranen, T., Sharfi, H., et al. (2011) · Nature Genetics · doi:10.1038/ng.890 · Cited by 1,120
c-Myc transactivation of LDH-A : Implications for tumor metabolism and growth
Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., & Dang, C. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6658 · Cited by 1,092
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., Gao, X., Aldape, K., & Lu, Z. (2011) · Nature · doi:10.1038/nature10598 · Cited by 1,028
Brick by brick: metabolism and tumor cell growth
DeBerardinis, R. J., Sayed, N., Ditsworth, D., & Thompson, C. B. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.02.003 · Cited by 1,018
Pyruvate kinase M2 is a phosphotyrosine-binding protein
Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06667 · Cited by 995
Targeting cellular metabolism to improve cancer therapeutics
Zhao, Y., Butler, E. B., & Tan, M. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.60 · Cited by 989
Gottlob, K., Majewski, N., Kennedy, S., Kandel, E., Robey, R. B., & Hay, N. (2001) · Genes & Development · doi:10.1101/gad.889901 · Cited by 961
MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities
Dang, C. V., Le, A., & Gao, P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0889 · Cited by 946
Walenta, S., Wetterling, M., Lehrke, M., Schwickert, G., Sundfør, K., Rofstad, E. K., & Mueller‐Klieser, W. (2000) · PubMed · Cited by 850
PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis
Yang, W., Xia, Y., Hawke, D., Li, X., Liang, J., Xing, D., Aldape, K., Hunter, T., Alfred Yung, W. K., & Lu, Z. (2012) · Cell · doi:10.1016/j.cell.2012.07.018 · Cited by 846
Causes and consequences of tumour acidity and implications for treatment
Stubbs, M., McSheehy, P. M. J., Griffiths, J. R., & Bashford, C. L. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01615-9 · Cited by 778
Lou, Y., McDonald, P. C., Oloumi, A., Chia, S., Ostlund, C., Ahmadi, A., Kyle, A., auf dem Keller, U., Leung, S., Huntsman, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4261 · Cited by 755
Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1
Ben-Sahra, I., Howell, J. J., Asara, J. M., & Manning, B. D. (2013) · Science · doi:10.1126/science.1228792 · Cited by 739
MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells
Sancho, P., Burgos-Ramos, E., Tavera, A., Bou Kheir, T., Jagust, P., Schoenhals, M., Barneda, D., Sellers, K., Campos-Olivas, R., Graña, O., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.08.015 · Cited by 722
The monocarboxylate transporter family—Structure and functional characterization
Halestrap, A. P. (2012) · IUBMB Life · doi:10.1002/iub.573 · Cited by 710
Hawley, S. A., Gadalla, A. E., Olsen, G. S., & Hardie, D. G. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2420 · Cited by 696
Multifaceted roles of glycolytic enzymes
Kim, J.-W., & Dang, C. V. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.01.005 · Cited by 682
Roesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., Körbel, C., Laschke, M. W., Gimotty, P. A., Philipp, S. E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.003 · Cited by 670
Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria
Bridges, H. R., Jones, A. J. Y., Pollak, M. N., & Hirst, J. (2014) · Biochemical Journal · doi:10.1042/bj20140620 · Cited by 661
Kim, J.-W., Gao, P., Liu, Y.-C., Semenza, G. L., & Dang, C. V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00440-07 · Cited by 658
Seyfried, T. N., & Shelton, L. M. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-7 · Cited by 644
Majewski, N., Nogueira, V., Bhaskar, P., Coy, P. E., Skeen, J. E., Gottlob, K., Chandel, N. S., Thompson, C. B., Robey, R. B., & Hay, N. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.11.014 · Cited by 633
�ber den Stoffwechsel der Carcinomzelle
Warburg, O. (1924) · Die Naturwissenschaften · doi:10.1007/bf01504608 · Cited by 631
Cancer metabolism: facts, fantasy, and fiction
Zu, X. L., & Guppy, M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.136 · Cited by 618
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 576
Mathupala, S. P., Ko, Y. H., & Pedersen, P. L. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.006 · Cited by 574
Feron, O. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.06.025 · Cited by 559
Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality
Chan, D. A., Sutphin, P. D., Nguyen, P., Turcotte, S., Lai, E. W., Banh, A., Reynolds, G. E., Chi, J.-T., Wu, J., Solow-Cordero, D. E., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002394 · Cited by 557
Liu, Y., Cao, Y., Zhang, W., Bergmeier, S., Qian, Y., Akbar, H., Colvin, R., Ding, J., Tong, L., Wu, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0131 · Cited by 555
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells
Israelsen, W. J., Dayton, T. L., Davidson, S. M., Fiske, B. P., Hosios, A. M., Bellinger, G., Li, J., Yu, Y., Sasaki, M., Horner, J. W., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.025 · Cited by 549
Raez, L. E., Papadopoulos, K., Ricart, A. D., Chiorean, E. G., DiPaola, R. S., Stein, M. N., Rocha Lima, C. M., Schlesselman, J. J., Tolba, K., Langmuir, V. K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2045-1 · Cited by 543
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., Wang, E., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7961 · Cited by 542
Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt
Robey, R. B., & Hay, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209595 · Cited by 536
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation
Holness, M. J., & Sugden, M. C. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311143 · Cited by 479
2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy
Zhang, D., Li, J., Wang, F., Hu, J., Wang, S., & Sun, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.003 · Cited by 462
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Dienstmann, R., Rodon, J., Serra, V., & Tabernero, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 462
Maschek, G., Savaraj, N., Priebe, W., Braunschweiger, P., Hamilton, K., Tidmarsh, G. F., De Young, L. R., & Lampidis, T. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3294 · Cited by 451
Clem, B., Telang, S., Clem, A., Yalcin, A., Meier, J., Simmons, A., Rasku, M. A., Arumugam, S., Dean, W. L., Eaton, J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0482 · Cited by 432
Lactate dehydrogenase a in cancer: A promising target for diagnosis and therapy: LDHA in Cancer
Miao, P., Sheng, S., Sun, X., Liu, J., & Huang, G. (2013) · IUBMB Life · doi:10.1002/iub.1216 · Cited by 422
Masui, K., Tanaka, K., Akhavan, D., Babic, I., Gini, B., Matsutani, T., Iwanami, A., Liu, F., Villa, G. R., Gu, Y., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.09.013 · Cited by 407
Systems analysis of intracellular pH vulnerabilities for cancer therapy
Persi, E., Duran-Frigola, M., Damaghi, M., Roush, W. R., Aloy, P., Cleveland, J. L., Gillies, R. J., & Ruppin, E. (2018) · Nature Communications · doi:10.1038/s41467-018-05261-x · Cited by 406
Mazur, P. K., Herner, A., Mello, S. S., Wirth, M., Hausmann, S., Sánchez-Rivera, F. J., Lofgren, S. M., Kuschma, T., Hahn, S. A., Vangala, D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3952 · Cited by 397
Cancer cell metabolism: implications for therapeutic targets
Jang, M., Kim, S. S., & Lee, J. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.85 · Cited by 397
Zhou, M., Zhao, Y., Ding, Y., Liu, H., Liu, Z., Fodstad, O., Riker, A. I., Kamarajugadda, S., Lu, J., Owen, L. B., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-33 · Cited by 395
18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
Weiler-Sagie, M., Bushelev, O., Epelbaum, R., Dann, E. J., Haim, N., Avivi, I., Ben-Barak, A., Ben-Arie, Y., Bar-Shalom, R., & Israel, O. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.067892 · Cited by 382
Rethinking the Warburg Effect with Myc Micromanaging Glutamine Metabolism
Dang, C. V. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3556 · Cited by 379
Emerging roles of PKM2 in cell metabolism and cancer progression
Luo, W., & Semenza, G. L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.06.010 · Cited by 376
Intracellular ATP Levels Are a Pivotal Determinant of Chemoresistance in Colon Cancer Cells
Zhou, Y., Tozzi, F., Chen, J., Fan, F., Xia, L., Wang, J., Gao, G., Zhang, A., Xia, X., Brasher, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1674 · Cited by 374
Infante, J. R., Somer, B. G., Park, J. O., Li, C.-P., Scheulen, M. E., Kasubhai, S. M., Oh, D.-Y., Liu, Y., Redhu, S., Steplewski, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.024 · Cited by 370
Targeting glucose metabolism for cancer therapy
Hamanaka, R. B., & Chandel, N. S. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120162 · Cited by 369
Role of monocarboxylate transporters in human cancers: state of the art
Pinheiro, C., Longatto-Filho, A., Azevedo-Silva, J., Casal, M., Schmitt, F. C., & Baltazar, F. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9428-1 · Cited by 368
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
NITULESCU, G. M., MARGINA, D., JUZENAS, P., PENG, Q., OLARU, O. T., SALOUSTROS, E., FENGA, C., SPANDIDOS, D. A., LIBRA, M., & TSATSAKIS, A. M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 364
Multimolecular Forms of Pyruvate Kinase from Rat and Other Mammalian Tissues*
IMAMURA, K., & TANAKA, T. (1972) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a129852 · Cited by 360
The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein
Feng, Z., & Levine, A. J. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.03.004 · Cited by 359
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP
Ko, Y. H., Smith, B. L., Wang, Y., Pomper, M. G., Rini, D. A., Torbenson, M. S., Hullihen, J., & Pedersen, P. L. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.047 · Cited by 352
Ko, Y. H., Pedersen, P. L., & Geschwind, J. F. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00667-x · Cited by 347
Enhancing Hematopoietic Stem Cell Transplantation Efficacy by Mitigating Oxygen Shock
Mantel, C. R., O’Leary, H. A., Chitteti, B. R., Huang, X., Cooper, S., Hangoc, G., Brustovetsky, N., Srour, E. F., Lee, M. R., Messina-Graham, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.054 · Cited by 337
Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways
Jia, D., Lu, M., Jung, K. H., Park, J. H., Yu, L., Onuchic, J. N., Kaipparettu, B. A., & Levine, H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816391116 · Cited by 336
Lu, C.-W., Lin, S.-C., Chen, K.-F., Lai, Y.-Y., & Tsai, S.-J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803508200 · Cited by 331
Metformin in cancer prevention and therapy.
Kasznicki, J., Śliwińska, A., & Drzewoski, J. (2014) · PubMed · doi:10.3978/j.issn.2305-5839.2014.06.01 · Cited by 316
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
Flaig, T. W., Gustafson, D. L., Su, L.-J., Zirrolli, J. A., Crighton, F., Harrison, G. S., Pierson, A. S., Agarwal, R., & Glodé, L. M. (2007) · Investigational New Drugs · doi:10.1007/s10637-006-9019-2 · Cited by 315
New aspects of the Warburg effect in cancer cell biology
Bensinger, S. J., & Christofk, H. R. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.02.003 · Cited by 307
Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters
Marchiq, I., & Pouysségur, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1307-x · Cited by 300
Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments
Draoui, N., & Feron, O. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.007724 · Cited by 296
Zhang, L., Huang, G., Li, X., Zhang, Y., Jiang, Y., Shen, J., Liu, J., Wang, Q., Zhu, J., Feng, X., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-108 · Cited by 293
Stein, M., Lin, H., Jeyamohan, C., Dvorzhinski, D., Gounder, M., Bray, K., Eddy, S., Goodin, S., White, E., & DiPaola, R. S. (2010) · The Prostate · doi:10.1002/pros.21172 · Cited by 291
Mohanti, B. K., Rath, G. K., Anantha, N., Kannan, V., Das, B. S., Chandramouli, B. A. R., Banerjee, A. K., Das, S., Jena, A., Ravichandran, R., et al. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)85017-6 · Cited by 281
Clinical role of positron emission tomography in oncology
Bomanji, J., Costa, D., & Ell, P. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00257-6 · Cited by 281
Lactate Activates HIF-1 in Oxidative but Not in Warburg-Phenotype Human Tumor Cells
De Saedeleer, C. J., Copetti, T., Porporato, P. E., Verrax, J., Feron, O., & Sonveaux, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046571 · Cited by 277
Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer
Clem, B. F., O'Neal, J., Tapolsky, G., Clem, A. L., Imbert-Fernandez, Y., Kerr, D. A., Klarer, A. C., Redman, R., Miller, D. M., Trent, J. O., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0097 · Cited by 276
Carnero, A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941865 · Cited by 272
Yu, L., Lu, M., Jia, D., Ma, J., Ben-Jacob, E., Levine, H., Kaipparettu, B. A., & Onuchic, J. N. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2074 · Cited by 272
Liou, G.-Y., Döppler, H., DelGiorno, K. E., Zhang, L., Leitges, M., Crawford, H. C., Murphy, M. P., & Storz, P. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.029 · Cited by 270
Jia, D., Park, J., Jung, K., Levine, H., & Kaipparettu, B. (2018) · Cells · doi:10.3390/cells7030021 · Cited by 270
Mitochondria in cancer: Not just innocent bystanders
Frezza, C., & Gottlieb, E. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.008 · Cited by 268
Singh, D., Banerji, A. K., Dwarakanath, B. S., Tripathi, R. P., Gupta, J. P., Mathew, T. L., Ravindranath, T., & Jain, V. (2005) · Strahlentherapie und Onkologie · doi:10.1007/s00066-005-1320-z · Cited by 266
Mitochondria-Targeted Drugs Synergize with 2-Deoxyglucose to Trigger Breast Cancer Cell Death
Cheng, G., Zielonka, J., Dranka, B. P., McAllister, D., Mackinnon, A. C., Joseph, J., & Kalyanaraman, B. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3928 · Cited by 263
Taylor, S., Spugnini, E. P., Assaraf, Y. G., Azzarito, T., Rauch, C., & Fais, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.004 · Cited by 259
Geschwind, J. F., Ko, Y. H., Torbenson, M. S., Magee, C. A., & Pedersen, P. L. (2002) · PubMed · Cited by 254
No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis
Bluemlein, K., Grüning, N.-M., Feichtinger, R. G., Lehrach, H., Kofler, B., & Ralser, M. (2011) · Oncotarget · doi:10.18632/oncotarget.278 · Cited by 253
Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer
Akins, N. S., Nielson, T. C., & Le, H. V. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180523111351 · Cited by 253
Cheong, J.-H., Park, E. S., Liang, J., Dennison, J. B., Tsavachidou, D., Nguyen-Charles, C., Wa Cheng, K., Hall, H., Zhang, D., Lu, Y., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0497 · Cited by 245
Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors
Dunbar, E. M., Coats, B. S., Shroads, A. L., Langaee, T., Lew, A., Forder, J. R., Shuster, J. J., Wagner, D. A., & Stacpoole, P. W. (2014) · Investigational New Drugs · doi:10.1007/s10637-013-0047-4 · Cited by 241
Kurtoglu, M., Gao, N., Shang, J., Maher, J. C., Lehrman, M. A., Wangpaichitr, M., Savaraj, N., Lane, A. N., & Lampidis, T. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0310 · Cited by 239
Simons, A. L., Ahmad, I. M., Mattson, D. M., Dornfeld, K. J., & Spitz, D. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3717 · Cited by 238
Identification of small molecule inhibitors of pyruvate kinase M2
Vander Heiden, M. G., Christofk, H. R., Schuman, E., Subtelny, A. O., Sharfi, H., Harlow, E. E., Xian, J., & Cantley, L. C. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.003 · Cited by 237
Lockhart, A. C., Rothenberg, M. L., Dupont, J., Cooper, W., Chevalier, P., Sternas, L., Buzenet, G., Koehler, E., Sosman, J. A., Schwartz, L. H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9237 · Cited by 232
Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression
Goldberg, M. S., & Sharp, P. A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111487 · Cited by 230
MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors
Birsoy, K., Wang, T., Possemato, R., Yilmaz, O. H., Koch, C. E., Chen, W. W., Hutchins, A. W., Gultekin, Y., Peterson, T. R., Carette, J. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2471 · Cited by 228
mTOR: on target for novel therapeutic strategies in the nervous system
Maiese, K., Chong, Z. Z., Shang, Y. C., & Wang, S. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.11.001 · Cited by 223
Nuclear PKM2 regulates the Warburg effect
Yang, W., & Lu, Z. (2013) · Cell Cycle · doi:10.4161/cc.26182 · Cited by 211
Dichloroacetate and cancer: New home for an orphan drug?
Kankotia, S., & Stacpoole, P. W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.08.005 · Cited by 210
Beyond Warburg effect – dual metabolic nature of cancer cells
Xie, J., Wu, H., Dai, C., Pan, Q., Ding, Z., Hu, D., Ji, B., Luo, Y., & Hu, X. (2014) · Scientific Reports · doi:10.1038/srep04927 · Cited by 207
Is there a role for carbohydrate restriction in the treatment and prevention of cancer?
Klement, R. J., & Kämmerer, U. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-75 · Cited by 206
Mechanism of antineoplastic activity of lonidamine
Nath, K., Guo, L., Nancolas, B., Nelson, D. S., Shestov, A. A., Lee, S.-C., Roman, J., Zhou, R., Leeper, D. B., Halestrap, A. P., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.08.001 · Cited by 205
Maher, J. C., Krishan, A., & Lampidis, T. J. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0724-7 · Cited by 204
Shen, Y.-C., Ou, D.-L., Hsu, C., Lin, K.-L., Chang, C.-Y., Lin, C.-Y., Liu, S.-H., & Cheng, A.-L. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.559 · Cited by 202
Liberti, M. V., Dai, Z., Wardell, S. E., Baccile, J. A., Liu, X., Gao, X., Baldi, R., Mehrmohamadi, M., Johnson, M. O., Madhukar, N. S., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.017 · Cited by 199
Locasale, J. W., & Cantley, L. C. (2010) · BMC Biology · doi:10.1186/1741-7007-8-88 · Cited by 198
PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion
Caino, M. C., Ghosh, J. C., Chae, Y. C., Vaira, V., Rivadeneira, D. B., Faversani, A., Rampini, P., Kossenkov, A. V., Aird, K. M., Zhang, R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500722112 · Cited by 197
Zhou, H., Zhang, B., Zheng, J., Yu, M., Zhou, T., Zhao, K., Jia, Y., Gao, X., Chen, C., & Wei, T. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.020 · Cited by 197
The role of glutathione in brain tumor drug resistance
Backos, D. S., Franklin, C. C., & Reigan, P. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.016 · Cited by 196
A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death
Wood, T. E., Dalili, S., Simpson, C. D., Hurren, R., Mao, X., Saiz, F. S., Gronda, M., Eberhard, Y., Minden, M. D., Bilan, P. J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0569 · Cited by 195
Belzacq, A.-S., El Hamel, C., Vieira, H. L. A., Cohen, I., Haouzi, D., Métivier, D., Marchetti, P., Brenner, C., & Kroemer, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204953 · Cited by 194
Dwarakanath, B., Singh, D., Banerji, A., Sarin, R., Venkataramana, N., Jalali, R., Vishwanath, P., Mohanti, B., Tripathi, R., Kalia, V., et al. (2009) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.55136 · Cited by 194
Colen, C. B., Shen, Y., Ghoddoussi, F., Yu, P., Francis, T. B., Koch, B. J., Monterey, M. D., Galloway, M. P., Sloan, A. E., & Mathupala, S. P. (2011) · Neoplasia · doi:10.1593/neo.11134 · Cited by 187
Proton channels and exchangers in cancer
Spugnini, E. P., Sonveaux, P., Stock, C., Perez-Sayans, M., De Milito, A., Avnet, S., Garcìa, A. G., Harguindey, S., & Fais, S. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.10.015 · Cited by 186
Mathupala, S. P., Ko, Y. H., & Pedersen, P. L. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.03.025 · Cited by 186
Zhao, F., Mancuso, A., Bui, T. V., Tong, X., Gruber, J. J., Swider, C. R., Sanchez, P. V., Lum, J. J., Sayed, N., Melo, J. V., et al. (2010) · Oncogene · doi:10.1038/onc.2010.67 · Cited by 179
Pértega-Gomes, N., Vizcaíno, J. R., Miranda-Gonçalves, V., Pinheiro, C., Silva, J., Pereira, H., Monteiro, P., Henrique, R. M., Reis, R. M., Lopes, C., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-312 · Cited by 178
Pitroda, S. P., Wakim, B. T., Sood, R. F., Beveridge, M. G., Beckett, M. A., MacDermed, D. M., Weichselbaum, R. R., & Khodarev, N. N. (2009) · BMC Medicine · doi:10.1186/1741-7015-7-68 · Cited by 177
Sotgia, F., Martinez-Outschoorn, U. E., Pavlides, S., Howell, A., Pestell, R. G., & Lisanti, M. P. (2011) · Breast Cancer Research · doi:10.1186/bcr2892 · Cited by 177
Chung, V., McDonough, S., Philip, P. A., Cardin, D., Wang-Gillam, A., Hui, L., Tejani, M. A., Seery, T. E., Dy, I. A., Al Baghdadi, T., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5383 · Cited by 176
Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine
Guo, L., Shestov, A. A., Worth, A. J., Nath, K., Nelson, D. S., Leeper, D. B., Glickson, J. D., & Blair, I. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.697516 · Cited by 176
Marchiq, I., Le Floch, R., Roux, D., Simon, M.-P., & Pouyssegur, J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2260 · Cited by 175
Wang, B.-Y., Zhang, J., Wang, J.-L., Sun, S., Wang, Z.-H., Wang, L.-P., Zhang, Q.-L., Lv, F.-F., Cao, E.-Y., Shao, Z.-M., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0194-x · Cited by 174
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
Zhang, Y.-J., Duan, Y., & Zheng, X. F. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.008 · Cited by 173
Hussien, R., & Brooks, G. A. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00177.2010 · Cited by 173
Fan, T., Sun, G., Sun, X., Zhao, L., Zhong, R., & Peng, Y. (2019) · Cancers · doi:10.3390/cancers11030317 · Cited by 171
Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate1
Pereira Da Silva, A. P., El-Bacha, T., Kyaw, N., Dos Santos, R. S., Da-Silva, W. S., Almeida, F. C. L., Da Poian, A. T., & Galina, A. (2009) · Biochemical Journal · doi:10.1042/bj20080805 · Cited by 170
Xu, D., Jin, J., Yu, H., Zhao, Z., Ma, D., Zhang, C., & Jiang, H. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0514-4 · Cited by 169
Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors
Di Cosimo, S., Ferretti, G., Papaldo, P., Carlini, P., Fabi, A., & Cognetti, F. (2003) · Drugs of Today · doi:10.1358/dot.2003.39.3.799451 · Cited by 166
Glyoxalase in tumourigenesis and multidrug resistance
Thornalley, P. J., & Rabbani, N. (2011) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2011.02.006 · Cited by 162
Lu, W., Hu, Y., Chen, G., Chen, Z., Zhang, H., Wang, F., Feng, L., Pelicano, H., Wang, H., Keating, M. J., et al. (2012) · PLoS Biology · doi:10.1371/journal.pbio.1001326 · Cited by 160
Carbonic Anhydrase Ix Inhibitors in Cancer Therapy: An Update
Supuran, C. T., & Winum, J.-Y. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.71 · Cited by 160
Ko, Y. H., Verhoeven, H. A., Lee, M. J., Corbin, D. J., Vogl, T. J., & Pedersen, P. L. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9417-4 · Cited by 159
Ganapathy‐Kanniappan, S., Geschwind, J.-F. H., Kunjithapatham, R., Buijs, M., Vossen, J. A., Tchernyshyov, I., Cole, R. N., Syed, L. H., Rao, P. P., Ota, S., et al. (2009) · PubMed · Cited by 157
Mitochondrial Oxidative Phosphorylation Is Regulated by Fructose 1,6-Bisphosphate
Díaz-Ruiz, R., Avéret, N., Araiza, D., Pinson, B., Uribe‐Carvajal, S., Devin, A., & Rigoulet, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800408200 · Cited by 155
Lu, C., Qin, L., Liu, H.-C., Candas, D., Fan, M., & Li, J. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121046 · Cited by 154
Metabolism-Based Therapeutic Strategies Targeting Cancer Stem Cells
Jagušt, P., de Luxán‐Delgado, B., Parejo-Alonso, B., & Sancho, P. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00203 · Cited by 154
Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
Dalva-Aydemir, S., Bajpai, R., Martinez, M. S., Adekola, K., Kandela, I. K., Wei, C., Singhal, S., Koblinski, J. E., Raje, N. S., Rosen, S. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1088 · Cited by 153
2-Deoxy-d-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer
Coleman, M. C., Asbury, C., Daniels, D. H., Du, J., Aykin‐Burns, N., Smith, B. J., Li, L., Spitz, D. R., & Cullen, J. J. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.08.032 · Cited by 153
Xu, X., Hausen, A. Z., Coy, J. F., & Löchelt, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.24078 · Cited by 151
Hypersensitization of Tumor Cells to Glycolytic Inhibitors
Liu, H., Hu, Y., Savaraj, N., Priebe, W., & Lampidis, T. J. (2001) · Biochemistry · doi:10.1021/bi002426w · Cited by 148
Chu, Q. S.-C., Sangha, R. S., Spratlin, J. L., Vos, L. J., Mackey, J. R., McEwan, A. J. B., Venner, P. M., & Michelakis, E. D. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0221-y · Cited by 146
Garcia, P. L., Miller, A. L., Kreitzburg, K. M., Gamblin, T. L., Christein, J. D., Heslin, M. J., Arnoletti, J. P., Richardson, J. H., Chen, D., Hanna, C. A., et al. (2015) · Oncogene · doi:10.1038/onc.2015.126 · Cited by 145
Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2
Li, W., Zheng, M., Wu, S., Gao, S., Yang, M., Li, Z., Min, Q., Sun, W., Chen, L., Xiang, G., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0530-4 · Cited by 144
Anti-VEGF– and anti-VEGF receptor–induced vascular alteration in mouse healthy tissues
Yang, Y., Zhang, Y., Cao, Z., Ji, H. L., Yang, X., Iwamoto, H., Wahlberg, E., Länne, T., Sun, B., & Cao, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301331110 · Cited by 143
Colombo, S. L., Palacios‐Callender, M., Frakich, N., de León, J., Schmitt, C. A., Boorn, L., Davis, N., & Moncada, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012362107 · Cited by 139
Sun, K., Tang, S., Hou, Y., Xi, L., Chen, Y., Yin, J., Peng, M., Zhao, M., Cui, X., & Liu, M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.025 · Cited by 138
Velpula, K. K., Bhasin, A., Asuthkar, S., & Tsung, A. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1868 · Cited by 136
Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C
Zeng, M., Lu, J., Li, L., Feru, F., Quan, C., Gero, T. W., Ficarro, S. B., Xiong, Y., Ambrogio, C., Paranal, R. M., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.017 · Cited by 136
Mikuriya, K., Kuramitsu, Y., Ryozawa, S., Fujimoto, M., Mori, S., Oka, M., Hamano, K., Okita, K., Sakaida, I., & Nakamura, K. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.4.849 · Cited by 135
Altered energy metabolism in cancer: A unique opportunity for therapeutic intervention
Zhang, Y., & Yang, J.-M. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.22958 · Cited by 132
Central role of lactic acidosis in cancer cell resistance to glucose deprivation‐induced cell death
Wu, H., Ding, Z., Hu, D., Sun, F., Dai, C., Xie, J., & Hu, X. (2011) · The Journal of Pathology · doi:10.1002/path.3978 · Cited by 132
Chen, X., Li, L.-Y., Guan, Y.-D., Yang, J., & Cheng, Y. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.47 · Cited by 131
Dai, W., Wang, F., Lu, J., Xia, Y., He, L., Chen, K., Li, J., Li, S., Liu, T., Zheng, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3800 · Cited by 128
Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed
Ferrari, S., Perut, F., Fagioli, F., del Prever, A. B., Meazza, C., Parafioriti, A., Picci, P., Gambarotti, M., Avnet, S., Baldini, N., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-268 · Cited by 128
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis
Chesney, J. A. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000241661.15514.fb · Cited by 128
The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R
Zhong, D., Xiong, L., Liu, T., Liu, X., Liu, X., Chen, J., Sun, S., Khuri, F. R., Zong, Y., Zhou, Q., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.005280 · Cited by 126
Wu, K.-H., Ho, C., Chen, Z.-F., Chen, L.-C., Whang‐Peng, J., Lin, T., & Ho, Y. (2017) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2017.03.009 · Cited by 126
3‐Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs
Ihrlund, L. S., Hernlund, E., Khan, O. M., & Shoshan, M. C. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.01.003 · Cited by 124
Hosaka, K., Yang, Y., Seki, T., Nakamura, M., Andersson, P., Rouhi, P., Yang, X., Jensen, L. D., Lim, S., Feng, N., et al. (2013) · Nature Communications · doi:10.1038/ncomms3129 · Cited by 124
Huber, V., Milito, A. D., Harguindey, S., Reshkin, S. J., Wahl, M., Rauch, C., Chiesi, A., Pouysségur, J., Gatenby, R. A., Rivoltini, L., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-57 · Cited by 119
Phase II Study of Lonidamine and Diazepam in the Treatment of Recurrent Glioblastoma Multiforme
Oudard, S. M., Carpentier, A., Banu, E., Fauchon, F., Célérier, D., Poupon, M. F., Dutrillaux, B., Andrieu, J. M., & Delattre, J. ‐. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1023756707900 · Cited by 117
Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells
Nakano, A., Tsuji, D., Miki, H., Cui, Q., Sayed, S. M. E., Ikegame, A., Oda, A., Amou, H., Nakamura, S., Harada, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027222 · Cited by 112
Understanding the metabolic basis of drug resistance
Martinez‐Outschoorn, U., Lin, Z., Ko, Y., Goldberg, A. F., Flomenberg, N., Wang, C., Pavlides, S., Pestell, R. G., Howell, A., Sotgia, F., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16584 · Cited by 111
Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy- d -glucose
Maher, J. C., Wangpaichitr, M., Savaraj, N., Kurtoğlu, M., & Lampidis, T. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0407 · Cited by 109
Zhou, Y., Yi, X., Stoffer, J. B., Bonafé, N., Gilmore-Hebert, M., McAlpine, J. N., & Chambers, S. K. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2170 · Cited by 106
Harada, N., Yasunaga, R., Higashimura, Y., Yamaji, R., Fujimoto, K., Moss, J., Inui, H., & Nakano, Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610724200 · Cited by 105
Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism
Kim, J. H., Lee, K. J., Seo, Y., Kwon, J.-H., Yoon, J. P., Kang, J. Y., Lee, H. J., Park, S. J., Hong, S. P., Cheon, J. H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18762-4 · Cited by 105
Kindler, H. L., Wroblewski, K., Wallace, J. A., Hall, M. J., Locker, G., Nattam, S., Agamah, E., Stadler, W. M., & Vokes, E. E. (2012) · Investigational New Drugs · doi:10.1007/s10637-010-9526-z · Cited by 103
Demarse, N. A., Ponnusamy, S., Spicer, E. K., Apohan, E., Baatz, J. E., Öğretmen, B., & Davies, C. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.09.062 · Cited by 102
Targeting PI 3‐kinase ( PI 3 K ), AKT and m TOR axis in lymphoma
Blachly, J. S., & Baiocchi, R. A. (2014) · British Journal of Haematology · doi:10.1111/bjh.13065 · Cited by 101
Cheng, G., Zielonka, J., McAllister, D. M., Tsai, S., Dwinell, M. B., & Kalyanaraman, B. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.272 · Cited by 100
Targeting the mTOR Signaling Pathway in Neuroendocrine Tumors
Chan, J. A., & Kulke, M. H. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0294-4 · Cited by 99
Kim, J. S., Ahn, K. J., Kim, J., Kim, H. M., Lee, J. D., Lee, J. M., Kim, S., & Park, J. H. (2008) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-008-9188-0 · Cited by 96
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
EMT Factors and Metabolic Pathways in Cancer
Georgakopoulos-Soares, I., Chartoumpekis, D. V., Kyriazopoulou, V., & Zaravinos, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00499 · Cited by 349
Crosstalk between glucose metabolism, lactate production and immune response modulation
Ye, L., Jiang, Y., & Zhang, M. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.11.001 · Cited by 306
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
You, M., Xie, Z., Zhang, N., Zhang, Y., Xiao, D., Liu, S., Zhuang, W., Li, L., & Tao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01442-3 · Cited by 292
Emerging therapies in cancer metabolism
Xiao, Y., Yu, T.-J., Xu, Y., Ding, R., Wang, Y.-P., Jiang, Y.-Z., & Shao, Z.-M. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.006 · Cited by 256
Metadata
- Authors
- Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 150
- Pages
- 104511
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2985781565
- Cited by
- 591
- References
- 261
- FWCI
- 14.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.